BRAF inhibitor therapy in HCL

Best Practice and Research: Clinical Haematology

Volumn 28, Issue 4, 2015, Pages 246-252

  Dietrich, Sascha ^a,b,c   Zenz, Thorsten ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

BRAF inhibitor; BRAF V600E; Dabrafenib; Hairy cell leukemia; MEK; Vemurafenib

Indexed keywords

DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; SULFONAMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG USE; GENE MUTATION; HAIRY CELL LEUKEMIA; HUMAN; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, HAIRY CELL; METABOLISM; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; PATHOLOGY; REMISSION; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMIDAZOLES; INDOLES; LEUKEMIA, HAIRY CELL; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM, RESIDUAL; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; REMISSION INDUCTION; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 84983209720     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2015.10.001     Document Type: Review

References (28)

1. E. Tiacci, A. Liso, M. Piris, and B. Falini Evolving concepts in the pathogenesis of hairy-cell leukaemia Nat Rev Cancer 6 6 2006 Jun 437 448
2. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, and et al. Mutations of the BRAF gene in human cancer Nature 417 6892 2002 Jun 27 949 954
3. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, and et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 6 2004 Mar 19 855 867
4. C.A. Pratilas, and D.B. Solit Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response Clin Cancer Res 16 13 2010 Jul 1 3329 3334
5. A. Korshunov, J. Meyer, D. Capper, A. Christians, M. Remke, H. Witt, and et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma Acta Neuropathol 118 3 2009 Sep 401 405
6. E. Tiacci, V. Trifonov, G. Schiavoni, A. Holmes, W. Kern, M.P. Martelli, and et al. BRAF mutations in hairy-cell leukemia N Engl J Med 364 24 2011 Jun 16 2305 2315
7. A. Jethwa, J. Hullein, T. Stolz, C. Blume, L. Sellner, A. Jauch, and et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia Br J Haematol 163 4 2013 Nov 496 500
8. M. Andrulis, R. Penzel, W. Weichert, A. von Deimling, and D. Capper Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia Am J Surg Pathol 36 12 2012 Dec 1796 1800
9. L. Arcaini, S. Zibellini, E. Boveri, R. Riboni, S. Rattotti, M. Varettoni, and et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms Blood 119 1 2012 Jan 5 188 191
10. P.A. Blombery, S.Q. Wong, C.A. Hewitt, A. Dobrovic, E.L. Maxwell, S. Juneja, and et al. Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders Haematologica 97 5 2012 May 780 783
11. S. Schnittger, U. Bacher, T. Haferlach, N. Wendland, M. Ulke, F. Dicker, and et al. Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia Blood 119 13 2012 Mar 29 3151 3154
12. S. Dietrich, H. Glimm, M. Andrulis, C. von Kalle, A.D. Ho, and T. Zenz BRAF inhibition in refractory hairy-cell leukemia N Engl J Med 366 21 2012 May 24 2038 2040
13. S. Dietrich, J. Hullein, M. Hundemer, N. Lehners, A. Jethwa, D. Capper, and et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia J Clin Oncol 31 19 2013 Jul 1 e300 e303
14. J.J. Waterfall, E. Arons, R.L. Walker, M. Pineda, L. Roth, J.K. Killian, and et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias Nat Genet 46 1 2014 Jan 8 10
15. S. Dietrich, J. Hullein, S.C. Lee, B. Hutter, D. Gonzalez, S. Jayne, and et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia Blood 2015 Jun 11 10.1182/blood-2015-04-643361
16. S. Dietrich, J. Hullein, S.C. Lee, B. Hutter, D. Gonzalez, S. Jayne, and et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia Blood 126 8 2015 Aug 20 1005 1008
17. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 Jun 30 2507 2516
18. A. Ribas, and K.T. Flaherty BRAF targeted therapy changes the treatment paradigm in melanoma Nat Rev Clin Oncol 8 7 2011 Jul 426 433
19. G.A. Follows, H. Sims, D.M. Bloxham, T. Zenz, M.A. Hopper, H. Liu, and et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib Br J Haematol 161 1 2013 Apr 150 153
20. F. Peyrade, D. Re, C. Ginet, L. Gastaud, M. Allegra, R. Ballotti, and et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation Haematologica 98 2 2013 Feb e20 e22
21. M.R. Grever How I treat hairy cell leukemia Blood 115 1 2010 Jan 7 21 28
22. J. Munoz, E. Schlette, and R. Kurzrock Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation J Clin Oncol 31 20 2013 Jul 10 e351 e352
23. H. Maurer, P. Haas, T. Wengenmayer, M. Lubbert, J. Duyster, and R. Zeiser Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis Ann Hematol 93 8 2014 Aug 1439 1440
24. J. Samuel, S. Macip, and M.J. Dyer Efficacy of vemurafenib in hairy-cell leukemia N Engl J Med 370 3 2014 Jan 16 286 288
25. C. Bailleux, G. Robert, C. Ginet, D. Re, A. Thyss, I. Sudaka, and et al. Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib Oncoscience 2 1 2015 44 49
26. V. Vergote, D. Dierickx, A. Janssens, G. Verhoef, T. Tousseyn, P. Vandenberghe, and et al. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib Ann Hematol 93 12 2014 Dec 2087 2089
27. J.S. Blachly, G. Lozanski, D.M. Lucas, M.R. Grever, K. Kendra, and L.A. Andritsos Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib J Natl Compr Canc Netw 13 1 2015 Jan 9 13 quiz
28. E. Tiacci, J.H. Park, L. De Carolis, S.S. Chung, A. Broccoli, S. Scott, and et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia N Engl J Med 2015 Sep 9 10.1056/NEJMoa1506583